The significant quality of life burden associated with symptoms of itching and/or skin pain in patients with atopic dermatitis (AD) may warrant alternate approaches to address unmet needs. Symptoms of ...
A US-based discrete choice experiment survey found that patients with atopic dermatitis (AD) prioritize treatments that effectively control itching. Because of the differences in health care and ...
Johnson & Johnson announced it will pay $1.25 billion to buy an experimental bispecific antibody targeting atopic dermatitis (AD) from Numab Therapeutics. The all-cash deal, which was announced ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to ...
Topical ruxolitinib appears to quickly relieve itch in Black patients with atopic dermatitis (AD), an industry-sponsored analysis of pooled data from two studies suggests. "Ruxolitinib cream ...
– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28 Results showed that patients with AD treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback